FDA leaders, facing doubts over the agency's independence, pledge to 'follow the science' amid pandemic

FDA Building 2
Leaders at the FDA are pledging to follow the science in the fight against the pandemic. (FDA)

After a series of controversial decisions by the FDA so far in the COVID-19 pandemic, questions have circled over whether politics are entering the agency's decision-making process. Aware of questions and criticisms surrounding the agency, key FDA leaders are pledging to always put science first.

In a USA Today op-ed, eight senior career officials said they “absolutely understand” that the agency faces political pressure, but that they will always use “sound science” as a “guide to navigate controversial waters.” 

“We will work with agency leadership to maintain FDA’s steadfast commitment to ensuring our decisions will continue to be guided by the best science,” the leaders wrote. “Our approach has been and must remain the gold standard that all can rely upon."

Virtual Roundtable

ESMO Post Show: Highlights from the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields. Register today.

The leaders oversee more than 17,000 employees and have more than 100 years of combined experience at the agency.

While they didn’t specifically touch on vaccines in the op-ed, the agency's reviews of immunizations will be among its biggest decisions amid the pandemic. President Donald Trump has indicated a vaccine is coming soon—possibly before the November election—and programs from Pfizer and Moderna are already in phase 3. AstraZeneca also has a phase 3 trial underway, but it's currently paused for a safety review. 

As the leaders know, trust in the agency is “vital.” If Americans don’t trust the agency, they’ll be less likely to use FDA-approved products or enroll in clinical studies, they wrote.

But that trust has been faltering, a new Kaiser Family Foundation survey shows. The group found that 62% of Americans believe the Trump administration will pressure the FDA to approve a vaccine that isn’t proven to be safe and effective. About 39% of Americans think the FDA and CDC are giving “too much attention” to political considerations, the survey found. 

RELATED: FDA chief Hahn walks back plasma claims, but his correction still missed the mark, experts say 

The FDA has stoked those worries with controversial moves in recent months. In August, the agency issued an emergency use authorization for convalescent plasma to treat hospitalized COVID-19 patients. In doing so, FDA commissioner Stephen Hahn said the treatment was associated with a “35% improvement in survival.” The number was inaccurate, and Hahn later said he intended to describe a “relative” risk reduction rather than an "absolute" risk reduction. 

But the treatment hadn’t been tested in a controlled trial, so experts said there wasn’t enough evidence to claim any benefit. As prominent physician Eric Topol saw it, the move was part of a trend. He wrote an op-ed calling on Hahn to “tell the truth or resign.” 

Before the plasma controversy, the FDA issued an emergency use authorization for hydroxychloroquine based on limited evidence. It later revoked the EUA when studies didn't show a benefit for the drug.

RELATED: Pfizer, AZ, Moderna and more pledge not to rush COVID-19 vaccines

Meanwhile, the FDA leaders aren't the only ones looking to reassure the public that they're basing their decision-making on science. The op-ed follows close on the heels of a rare joint pledge from 9 biopharma companies to follow the data and not rush their vaccine programs.

Read more on

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.